Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.

Circulating IGF-I and -II are bound to specific insulin-like growth factor (IGF)-binding proteins (IGFBPs), of which IGFBP-3 binds the majority of the IGFs. IGFBP-3 levels are regulated by GH and have been suggested to provide additional information on GH secretory capacity compared to IGF-I. However, the diagnostic value of IGFBP-3 is still controversial, perhaps because the quality of the available normative data for IGFBP-3 varies. It has recently been shown that a large number of individuals is required to establish reference ranges for IGF-I that take into account age, sex, body mass index (BMI), and pubertal stage. Therefore, we measured IGFBP-3, IGF-I, IGF-II, IGFBP-1, and IGFBP-2 levels by RIA in 907 healthy children to establish well characterized normative data on IGFBP-3 according to age, sex, and pubertal stage and to study the complex relationship between IGFs and their BPs in puberty. We found that IGFBP-3 levels increase with age in children, with maximal levels in puberty; girls experience peak values approximately 1 yr earlier than boys. Age, sex, height, BMI, and pubertal maturation were all important factors in determining the circulating levels of IGFBP-3, whereas IGF-I levels were unaffected by BMI. Comparison of IGFBP-3 with IGF-1 concentrations revealed that they did not exhibit the same developmental pattern in puberty. IGF-I levels increased to relatively higher levels than IGFBP-3, leading to an increasing molar ratio between IGF-I and IGFBP-3 in puberty, when growth velocity is high. Concomitantly, IGF-II and IGFBP-2 levels were unchanged throughout puberty, whereas IGFBP-1 levels declined with age in prepubertal children, with lowest values in puberty. There was a highly significant correlation between IGF-I and -II and IGFBP-3 on a molar basis (r = 0.84; P < 0.0001). Thus, we speculate that IGFBP-3 is pivotal for circulating IGF bioactivity and that the increase in the molar ratio between IGF-I and IGFBP-3 reflects an increase in free, biologically active IGF-I. In conclusion, we have provided normative data on a large group of healthy individuals and conclude that age, sex, height, BMI, and pubertal maturation have to be taken into account before a single IGFBP-3 value in a growth-retarded child can be evaluated properly.

[1]  N. Skakkebaek,et al.  The ratio between serum levels of insulin‐like growth factor (IGF)‐I and the IGF binding proteins (IGFBP‐1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients , 1994, Clinical endocrinology.

[2]  N. Skakkebaek,et al.  Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. , 1994, European journal of endocrinology.

[3]  Y. Hasegawa,et al.  Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency. , 1994, European journal of endocrinology.

[4]  R. Baxter,et al.  Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. , 1994, Endocrinology.

[5]  N. Skakkebaek,et al.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. , 1994, The Journal of clinical endocrinology and metabolism.

[6]  J. Souberbielle,et al.  Diagnostic markers of permanent idiopathic growth hormone deficiency. , 1994, The Journal of clinical endocrinology and metabolism.

[7]  J. Argente,et al.  Normative data for insulin-like growth factors (IGFs), IGF-binding proteins, and growth hormone-binding protein in a healthy Spanish pediatric population: age- and sex-related changes. , 1993, The Journal of clinical endocrinology and metabolism.

[8]  C. Sklar,et al.  Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. , 1993, Acta endocrinologica.

[9]  M. Stene,et al.  Plasma IGFBP‐3 and its relationship with quantitative growth hormone secretion in short children * , 1993, Clinical endocrinology.

[10]  M. Ranke,et al.  Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. , 1993, The Journal of clinical endocrinology and metabolism.

[11]  M. Ranke,et al.  Clinical studies of IGFBP-2 by radioimmunoassay. , 1993, Growth regulation.

[12]  I. Litt,et al.  Insulin-like growth factor binding protein-3 in normal pubertal girls. , 1992, Acta endocrinologica.

[13]  Y. Hasegawa,et al.  Western ligand blot assay for human growth hormone-dependent insulin-like growth factor binding protein (IGFBP-3): the serum levels in patients with classical growth hormone deficiency. , 1992, Endocrinologia japonica.

[14]  K. Hall,et al.  Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. , 1991, Acta endocrinologica.

[15]  M. Ranke,et al.  Circadian patterns of serum insulin-like growth factor (IGF) II and IGF binding protein 3 in growth hormone-deficient patients and age- and sex-matched normal subjects. , 1990, Acta endocrinologica.

[16]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[17]  H. Zeisel,et al.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. , 1990, The Journal of clinical endocrinology and metabolism.

[18]  Darrell M. Wilson,et al.  Efficacy of Insulin-Like Growth Factor I Levels in Predicting the Response to Provocative Growth Hormone Testing , 1990, Pediatric Research.

[19]  E. Froesch,et al.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. , 1989, Acta endocrinologica.

[20]  D. Dunger,et al.  RELATIONSHIP BETWEEN THE PUBERTAL FALL INSEX HORMONE BINDING GLOBULIN AND INSULIN‐LIKE GROWTH FACTOR BINDING PROTEIN‐I. A SYNCHRONIZED APPROACH TO PUBERTAL DEVELOPMENT? , 1989, Clinical endocrinology.

[21]  M. Ranke,et al.  A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. , 1988, Acta endocrinologica.

[22]  R. Furlanetto,et al.  A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. , 1987, American journal of diseases of children.

[23]  R. Baxter,et al.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. , 1986, The Journal of clinical investigation.

[24]  D. Wilson,et al.  Insulin-like growth factors I and II in evaluation of growth retardation. , 1986, The Journal of pediatrics.

[25]  Y. Le Bouc,et al.  Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents. , 1984, The Journal of clinical endocrinology and metabolism.

[26]  K. Hall,et al.  Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. , 1984, Acta endocrinologica.

[27]  E. Froesch,et al.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. , 1981, The Journal of clinical investigation.

[28]  K. Hall,et al.  Somatomedin A levels in serum from healthy children and from children with growth hormone deficiency or delayed puberty. , 1980, Acta endocrinologica.

[29]  R. Furlanetto,et al.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. , 1977, The Journal of clinical investigation.

[30]  J. V. Van Wyk,et al.  Serum somatomedin-C in hypopituitarism and in other disorders of growth. , 1977, The Journal of pediatrics.